PharmaVitae: Company Comparator Tool
The Comparator Tool builds from the PharmaVitae profiles of the 50 leading pharma companies. Updated monthly, the tool allows you to compare the 50 players by current and forecast sales to 2012.
|
 |
02/29/2008 |
$45600.00 |
| |
|
|
|
Stakeholder Insight: Acute Coronary Syndromes Fresh look at ACS in Europe, what is the real picture?
The face of ACS is changing. The ageing population and pressure of growing risk factors have made a significant impact on the management strategies in ACS....
|
|
12/26/2007 |
$30400.00 |
| |
|
|
|
Stakeholder Insight: Acute Coronary Syndromes ACS in Europe, what is the best practice?
The face of ACS continues to change. The ageing population and pressure of growing risk factors have made a significant impact on the management strategies in ACS....
|
|
12/25/2008 |
$30400.00 |
| |
|
|
|
The Clinical Chemistry And Immunodiagnostics Market: A 7-Country Market Survey
|
|
08/01/1997 |
$29400.00 |
| |
|
|
|
Molecular Diagnostics Market: DNA Probes and Biochips -- New Product Development Opportunities and Business Expansion Strategies for Instrument and Reagent Suppliers
The molecular diagnostics market is unquestionably the most rapidly growing segment of the in vitro diagnostics industry. The next ten years will witness significant developments in reagent systems and automation, as well as the introduction of a wide range of new products that will require innovative marketing approaches....
|
|
|
$27500.00 |
| |
|
|
|
The Blood Banking Market: US, Europe, Japan - Emerging Opportunities and Business Development Strategies
During the next ten years, the blood banking market will undergo significant transformation, which will result from the convergence of several trends, including more stringent regulations advances in diagnostic technologies, IT, system engineering and automation; and intensifying competition. Some segments will start resembling commodity markets, where product positioning and differentiation is more critical than underlying technology....
|
|
|
$27000.00 |
| |
|
|
|
Infectious Disease Testing Market: US, Europe, Japan--Emerging Opportunities and Business Strategies
The infectious disease testing market is one of the most rapidly growing segments of the in vitro diagnostics industry, and the greatest challenge facing suppliers in the 21st century. Among the main driving forces behind the growth of this dynamic market is continuous spread of AIDS, which remains the world's major health threat and a major factor contributing to the rise in incidence of opportunistic infections bioterrorism advances in molecular diagnostic technologies and a wider availability of immunosuppressive drugs....
|
|
|
$25800.00 |
| |
|
|
|
The Cancer Diagnostics Market: US, Europe, Japan - Emerging Opportunities and Business Expansion Strategies
The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next ten years, the worldwide cancer testing market is promising to be an exciting, dynamic and rapidly expanding field....
|
|
|
$24500.00 |
| |
|
|
|
The 2009 Coagulation Testing Market: US, Europe, Japan - Emerging Business Opportunities and Market Expansion Strategies for Suppliers
The growing cost-containment pressures in major industrialized nations, coupled with continued technological advances in chromagenic substrates, monoclonal antibodies, immunoassays, molecular diagnostics, computers and laboratory automation will radically change the coagulation testing practice during the next ten years. New specific and sensitive markers of hemostasis will be increasingly used on automated instrumentation....
|
|
|
$23700.00 |
| |
|
|
|
Commercial Insight: Solid organ transplantation - The impact of new biologics, generics and reformulations
The transplant immunosuppressant market has seen considerable growth in recent years, but this is expected to slow down. Two factors combine to cause a decline in the market from 2011, the limited availability of donor organs and patent expiries of several key products....
|
|
12/18/2008 |
$15400.00 |
| |
|
|
|
Commercial and Pipeline Insight: Influenza Vaccines - Pandemic threat revitalizes the sector
The influenza vaccine market, sized at approximately $2.2 billion in 2006, yields many challenges....
|
|
04/06/2007 |
$15200.00 |
| |
|
|
|
Pipeline/Commercial Insight: Supportive Care in Oncology - Significant growth opportunities exist in new supportive care indications
Supportive care can be defined as those products used to prevent and/or treat the adverse side effects that arise as a result of the tumor itself or administration of anticancer therapies, in particular cytotoxic chemotherapy. While the antihormonal therapies and novel molecular targeted therapies do not exist without some toxicity, these are not as severe as those associated with chemotherapy.
|
|
06/15/2007 |
$15200.00 |
| |
|
|
|
Commercial Insight: Depression - Atypical lifecycle management strategy rejuvenates depression market
Novel pipeline drugs, lifecycle management of the current branded antidepressants, and development of atypical antipsychotics for depression are set to grow the depression market through to 2010 when it will peak at $14.6 billion....
|
|
06/27/2007 |
$15200.00 |
| |
|
|
|
Commercial Insight: Insomnia - Strong brand identity critical to differentiation in an increasingly crowded market
Ambien has remained the clear leader in the insomnia market for over a decade, with 2006 sales of over $2.3 billion across the seven major markets....
|
|
06/27/2007 |
$15200.00 |
| |
|
|
|
Commercial Insight: Multiple Sclerosis - Continued growth makes the MS market a highly attractive investment
The dynamic MS market continues to grow unabated; seven major market revenues increased 14.7% from 2005 to $4....
|
|
06/27/2007 |
$15200.00 |
| |
|
|
|
Commercial Insight: Osteoporosis - Risk management and reformulation offer best defense against generic onslaught
The osteoporosis market is due a major upheaval when market leader Fosamax (alendronate) loses its US patent. The resultant heightened competition will force market players to implement radical lifecycle management strategies to safeguard their franchise revenue....
|
|
06/27/2007 |
$15200.00 |
| |
|
|
|
Commercial Insight: Top 20 Cancer Therapy Brands - Sales of targeted therapies overtake cytotoxics in 2006
Sales of the Top 20 cancer therapy brands in each of the seven major markets totaled $24.5 billion in 2006 and are forecast to grow at a CAGR of 6....
|
|
07/02/2007 |
$15200.00 |
| |
|
|
|
Commercial Insight: Asthma & COPD - Combination products still have blockbuster potential
Detailed analysis of the Asthma and COPD market. 10 year sales forecast for all major drugs brands in these indications, taking into account new treatment trends, clinical trial data, patent expirations and key new product launches in the 7 major markets.
|
|
07/11/2007 |
$15200.00 |
| |
|
|
|